Timing clarification: IFF is scheduled to release results after the market closes today, Tuesday, August 4, 2026. The earnings call is tomorrow, Wednesday, August 5, at 9:00 a.m. ET. (ir.iff.com)
This report is less about whether IFF can produce a modest quarterly beat and more about whether management can preserve its full-year margin and cash-flow story after warning that Q2 would be the most difficult part of 2026.
IFF entered the quarter with good momentum. First-quarter comparable currency-neutral sales grew 3%, adjusted operating EBITDA rose 8% to $568 million, and free cash flow improved by $144 million year over year to $92 million. However, management explicitly said Q2 EBITDA would fall below Q1 because of:
The subsequent agreement to sell Food Ingredients has substantially improved the strategic picture, but the near-term earnings question remains: Can productivity and core-business growth offset the expected price-cost squeeze? (ir.iff.com)
Current LSEG consensus published on IFF’s investor-relations site is approximately:
| Metric | Q2 2026 consensus | Range |
|---|---|---|
| Sales | $2.692 billion | $2.660B–$2.772B |
| Adjusted operating EBITDA | $530 million | $518M–$538M |
| Adjusted EPS | $1.12 | $1.05–$1.14 |
| Implied EBITDA margin | 19.7% | — |
For the full year, consensus stands at roughly $10.74 billion of sales, $2.107 billion of adjusted operating EBITDA and $4.46 of adjusted EPS. That places EBITDA expectations almost exactly at the midpoint of IFF’s existing $2.05 billion–$2.15 billion guidance. (ir.iff.com)
Reported year-over-year sales comparisons will remain distorted by divestitures. Investors should prioritize comparable currency-neutral growth, segment margins and the underlying volume/price mix rather than the headline reported revenue change.
Consensus calls for EBITDA to decline from $568 million in Q1 to about $530 million in Q2, consistent with management’s warning. That by itself should not be alarming.
The important issue is the explanation:
A result around consensus with credible evidence that Q2 was the margin trough would be constructive. Conversely, a miss caused by persistent price-cost pressure—not merely timing—would raise doubts about the full-year EBITDA range.
Scent was already IFF’s weakest segment in Q1. Comparable currency-neutral sales rose only 1%, while adjusted operating EBITDA declined 2% as unfavorable price-to-input costs offset volume growth and productivity.
There are two separate issues to monitor:
Investors should distinguish a temporary regional disruption from a broader deterioration in fragrance demand. Evidence that Fine Fragrance orders and customer supply chains are normalizing would support the expected second-half recovery. Continued weakness outside the Middle East would be more concerning.
The commodity portion of Fragrance Ingredients is a longer-term structural issue. Management has said it will deemphasize external commodity sales while investing in specialty, natural, synthetic and biotech molecules. Q2 should provide an update on whether this repositioning is reducing the segment’s earnings drag.
IFF’s pricing cycle typically lags cost inflation. Management entered Q2 implementing surcharges for logistics and energy, with broader raw-material pricing expected to build later.
Watch for three disclosures:
A modestly negative Q2 price-cost relationship is already embedded in expectations. The risk is that customer negotiations take longer than anticipated or that raw-material inflation accelerates before surcharges take effect.
The best outcome would be management confirming that logistics and energy surcharges are largely in place and that the second-half earnings bridge remains intact.
Q1 growth was broad-based and volume-led:
Management said it had not seen evidence of meaningful customer prebuying. Q2 will test that assertion.
Particular areas to watch:
A small sales beat driven by volume would be more valuable than a larger beat dependent on currency or short-lived pricing.
IFF agreed in late May to sell Food Ingredients to CVC in a transaction valuing the business at approximately $4.3 billion. IFF expects approximately $3.8 billion of net cash proceeds and a minority interest currently valued at about $200 million, representing roughly 9.9% of the future company. The transaction is expected to close by the end of Q2 2027, subject to regulatory approvals and other conditions. (ir.iff.com)
This is now central to the investment case. The report and call should address:
The sale simplifies IFF into three more innovation-oriented businesses and should significantly reduce leverage. But investors still need enough detail to judge the earnings dilution and how quickly stranded costs can be removed.
IFF also announced in July that it would sell a portfolio of botanical extracts, vitamins, minerals and food-enhancement activities generating approximately $170 million of 2025 revenue. Financial terms were not disclosed, and closing is expected by year-end 2026. This reinforces the portfolio-simplification strategy but may require another adjustment to guidance or the comparable revenue base. (ir.iff.com)
Cash flow remains one of the most important markers of execution.
Q1 free cash flow reached $92 million, versus negative $52 million a year earlier, while net debt to credit-adjusted EBITDA finished at approximately 2.5x. Management expects a meaningful full-year cash-flow improvement, driven by:
The company has not provided a firm full-year free-cash-flow target because of portfolio uncertainty. Investors should look for greater specificity now that the Food Ingredients transaction has been signed.
Also relevant is IFF’s $1 billion delayed-draw term loan arranged in June to refinance €800 million of notes due in September 2026. The facility is expected to be repaid from the Food Ingredients sale proceeds if drawn. This addresses the near-term maturity, but management should explain the likely interim interest-cost impact.
Current full-year guidance is:
Consensus EBITDA of approximately $2.107 billion is essentially at the midpoint, meaning expectations do not require a guidance increase. The market is more likely to focus on whether management:
A simple reaffirmation accompanied by improving second-half price-cost commentary would probably be sufficient. A reduction in the EBITDA midpoint after the strong Q1 beat would imply that Q2 pressures were greater or more persistent than management originally expected.
IFF has already delivered the major strategic catalyst investors were awaiting: a signed agreement to sell Food Ingredients at a substantial valuation. This quarter therefore needs to validate the operating side of the thesis.
The most important question is not whether Q2 EBITDA declines sequentially—that was clearly telegraphed. It is whether management can demonstrate that:
A clean quarter near consensus with unchanged guidance and a convincing second-half recovery bridge should be viewed positively. The principal downside risk is evidence that Scent and inflation pressures are persisting beyond Q2, eroding the cushion created by the strong first quarter.